Pacific Biosciences of California entered into a sales agreement with Allen & Company LLC to establish an at-the-market (ATM) equity offering program. The company may sell up to $100 million of its common stock from time to time at its discretion. Allen & Company will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds.
Pacific Biosciences reported total revenue of $40.6 million for Q3 2026, a slight increase from $38.4 million in the prior year. The company recorded a net loss of $37.8 million for the quarter, showing improvement over the $506.0 million net loss in the nine-month period of 2025 which was heavily impacted by significant intangible asset amortization and impairment charges.
Pacific Biosciences of California Financial Results
Pacific Biosciences reported Q3 2026 revenue of $40.6 million, driven by demand for its Revio and Vega sequencing systems. Alongside the results, the company announced that CFO Jim Gibson has stepped down and transitioned to an advisory role, with CEO Mark Van Oene serving as interim CFO during a search for a permanent successor.
Term
Q3 2026
“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth.”
Mark Van Oene, President and Chief Executive Officer